全文获取类型
收费全文 | 422904篇 |
免费 | 33141篇 |
国内免费 | 13887篇 |
专业分类
耳鼻咽喉 | 3174篇 |
儿科学 | 6243篇 |
妇产科学 | 5706篇 |
基础医学 | 61857篇 |
口腔科学 | 7686篇 |
临床医学 | 31496篇 |
内科学 | 67740篇 |
皮肤病学 | 5482篇 |
神经病学 | 31439篇 |
特种医学 | 11404篇 |
外国民族医学 | 65篇 |
外科学 | 30971篇 |
综合类 | 59811篇 |
现状与发展 | 55篇 |
一般理论 | 14篇 |
预防医学 | 27907篇 |
眼科学 | 4934篇 |
药学 | 59188篇 |
102篇 | |
中国医学 | 21334篇 |
肿瘤学 | 33324篇 |
出版年
2024年 | 1011篇 |
2023年 | 6555篇 |
2022年 | 14705篇 |
2021年 | 19098篇 |
2020年 | 14843篇 |
2019年 | 13360篇 |
2018年 | 13275篇 |
2017年 | 14123篇 |
2016年 | 14590篇 |
2015年 | 15546篇 |
2014年 | 21702篇 |
2013年 | 27172篇 |
2012年 | 23412篇 |
2011年 | 27196篇 |
2010年 | 20478篇 |
2009年 | 20721篇 |
2008年 | 21947篇 |
2007年 | 21823篇 |
2006年 | 19925篇 |
2005年 | 18105篇 |
2004年 | 15144篇 |
2003年 | 13423篇 |
2002年 | 10619篇 |
2001年 | 9233篇 |
2000年 | 7769篇 |
1999年 | 6804篇 |
1998年 | 5829篇 |
1997年 | 5623篇 |
1996年 | 5078篇 |
1995年 | 4387篇 |
1994年 | 4139篇 |
1993年 | 3459篇 |
1992年 | 3049篇 |
1991年 | 2873篇 |
1990年 | 2417篇 |
1989年 | 2007篇 |
1988年 | 1897篇 |
1987年 | 1661篇 |
1986年 | 1529篇 |
1985年 | 2300篇 |
1984年 | 2000篇 |
1983年 | 1428篇 |
1982年 | 1516篇 |
1981年 | 1235篇 |
1980年 | 1114篇 |
1979年 | 866篇 |
1978年 | 588篇 |
1977年 | 489篇 |
1976年 | 467篇 |
1975年 | 334篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
《Drug metabolism and pharmacokinetics》2020,35(1):56-70
Hepatic uptake mediated by organic anion transporting polypeptide (OATP) 1B1 and 1B3 can serve as a major elimination pathway for various anionic drugs and as a site of drug-drug interactions (DDIs). This article provides an overview of the in vitro approaches used to predict human hepatic clearance (CLh) and the risk of DDIs involving OATP1Bs. On the basis of the so-called extended clearance concept, in vitro–in vivo extrapolation methods using human hepatocytes as in vitro systems have been used to predict the CLh involving OATP1B-mediated hepatic uptake. CLh can be quantitatively predicted using human donor lots possessing adequate OATP1B activities. The contribution of OATP1Bs to hepatic uptake can be estimated by the relative activity factor, the relative expression factor, or selective inhibitor approaches, which offer generally consistent outcomes. In OATP1B1 inhibition assays, substantial substrate dependency was observed. The time-dependent inhibition of OATP1B1 was also noted and may be a mechanism underlying the in vitro–in vivo differences in the inhibition constant of cyclosporine A. Although it is still challenging to quantitatively predict CLh and DDIs involving OATP1Bs from only preclinical data, understanding the utility and limitation of the current in vitro methods will pave the way for better prediction. 相似文献
122.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献123.
目的探讨体外转染细胞周期素A2(Cyclin A2)基因对原代大鼠心肌细胞增殖的影响,为心脏再生提供细胞学依据。方法 SD乳鼠12只,分离、培养、鉴定原代乳鼠心肌细胞并分为3组,实验组:转染带有强化绿色荧光蛋白(GFP)和Cyclin A2基因的重组腺病毒(Ad-Cyclin A2-GFP);空病毒组:转染不含目的基因带有GFP的重组腺病毒(Ad-Null-GFP);阴性对照组:未做转染处理,仅加入等量的培养基。利用GFP示踪技术,评估原代心肌细胞转染效率;转染后的细胞继续体外培养3~5d,利用免疫荧光技术分别检测Cyclin A2、磷酸化组蛋白H3(H3P)、心肌肌钙蛋白-T(c Tn T)。结果 1.荧光GFP示踪表明原代心肌细胞的转染效率高达(97±0.74)%;2.免疫荧光标记显示,空病毒组和对照组结果相似;心肌细胞特异性标记蛋白c Tn T分布于细胞质,原代心肌细胞纯度高达(95±0.62)%;心肌细胞Cyclin A2主要在胞核内聚集,少数分布于细胞质。H3P为核蛋白在细胞核内分布。3.转染Cyclin A2后,实验组H3P阳性率明显高于空病毒组和对照组,差异具有统计学意义(P0.05);实验组可见大量多核细胞,以双核为主,伴少量3核细胞。结论腺病毒作为转染载体对原代心肌细胞有很好的侵染效率;Cyclin A2超表达促进原代心肌细胞形成双核。 相似文献
124.
125.
126.
2型糖尿病及骨质疏松已成为我国最主要的慢性代谢性疾病。2型糖尿病常伴有血脂紊乱,常表现为低密度脂蛋白升高,而越来越多的研究表明血脂通过不同的方式影响骨代谢,其机制可能是通过抑制骨髓间充质干细胞成骨分化,通过RANK/RNAKL/OPG信号通路及炎症反应调节破骨细胞等方式调节骨代谢。 相似文献
127.
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecular subtypes can be identified in HER2+ tumors, with the HER2-enriched being the most frequent. Such subtypes do not differ much from their counterparts in HER2-negative disease, apart for the high expression of genes in/near the HER2 amplicon on chromosome 17. Intrinsic subtyping, along with the quantification of ERBB2 mRNA levels, is associated with higher rates of pathologic complete response across neoadjuvant trials of dual HER2 blockade and might help select patients for de-escalation and escalation treatment strategies. Secondly, HER2+ tumors have a broad range of DNA alterations. ERBB2 mutations and alterations in the PI3K/Akt/mTOR pathway are among the most frequent and might predict benefit from potent pan-HER, PI3K and mTOR inhibitors. Moreover, HER2+ tumors are usually infiltrated by lymphocytes. These tumor infiltrating-lymphocytes (TILs) predict response to neoadjuvant anti-HER2-based treatment and exert a prognostic role. PD-L1, detected in ∼42 % of HER2+ BC, might also be useful to define patients responding to novel anti-PD1/PD-L1 immunotherapies. New multiparametric clinicopathologic and genomic tools accounting for this complexity, such as HER2DX, are under development to define more tailored treatment approaches. Finally, HER2-targeted antibody-drug conjugates (ADC) such as trastuzumab deruxtecan might be active in tumors with low expression of HER2. Overall, there is a need to molecularly characterize and develop novel targeted therapies for HER2+ disease. 相似文献
128.
129.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献